Author Index

VOLUME 23, 2002

Bae, Kyongtae, 97
Baran, Jane A., 327
Bellis, Teri James, 287
Berlin, Charles I., 201, 209
Binzer, Susan, 3
Brashears, Shanda, 201, 209

Canlon, Barbara, 13
Chermak, Gail D., 297
Cohen, Lawrence T., 97

Davis, Wes II, 277
Doucet, Kathrine, 43

Enrietto, Jane, 77
Erber, Norman P., 35

Feldman, Irit, 357
Ferre, Jeanane M., 319
Formby, Craig, 21, 179
Franck, Kevin H., 225

Gagne, Jean-Pierre, 43
Gans, Richard E., 105, 129, 149
Gates, George A., 97
Geers, Ann, 1, 101
Gerdes, Marsha, 225
Gold, Susan L., 21, 179
Grimes, Alison M., 181

Hall, James W. III, 277
Harding, Gary W., 97
Hare, Christine, 263
Harrington-Gans, Patricia, 129
Hester, T. Oma, 107
Hildesheimer, Minka, 357
Holden, Laura K., 97
Hood, Linda J., 201, 209

Jacobson, Gary P., 161
Jirsa, Robert E., 349

Keller, Warren D., 337
Ketten, Darlene R., 97
Kidd, Gary, 83
Killion, Mead, 57
Kletzker, G. Robert, 97
Kuhl, Patricia K., 99
Kushnir, Dana, 357

Labelle, Maude, 43
Laplante-Levesque, Ariane, 43
Li, Li, 201
Lombardo, Michael, 143

Miran, Dana, 357
Montoya, Louise A., 225
Morlet, Thierry, 201, 209
Muchnik, Chava, 357
Musiek, Frank E., 263, 297

Neely, J. Gail, 97

O'Leary, Dennis, 121

Phillips, Dennis P., 251
Pikus, Anita, 113
Putter-Katz, Hanna, 357

Rainey, Dawne M., 225
Rose, Kelly, 201, 209
Rosenberg, Gail Gegg, 309

Said, Limor Adi-Ben, 357
Shallop, Jon K., 215
Shinn, Jennifer, 263
Silverstein, Herbert, 107
Sininger, Yvonne S., 193
Skinner, Margaret W., 97
Smith, Peter G., 97
Sommers, Mitchell S., 95
Spehar, Brent, 95
Stredler-Brown, Arlene, 239

Tedesco, Sonya, 201
Tillery, Kim L., 337
Tlumak, Abreena I., 183
Tye-Murray, Nancy, 95

Valente, Michael, 77

Watson, Charles, 83
Wertz, Diane, 277
Whiting, Bruce R., 97

Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Subject Index

VOLUME 23, 2002

AI (Articulation Index), 57, 63
  count-the-dots testing, 57–58, 64–65
American Sign Language (ASL), 213
Americans with Disabilities Act (ADA), 9
ASHA (American Speech-Language and Hearing Association), 44, 54
Attention Deficit Hyperactivity Disorder (ADHD), 337–338
  differential diagnosis and co-morbidity with APD, 340–345
Attention Deficit Hyperactivity Disorder (ADHD) vs. Auditory Processing Disorders (APD), 338–341
Audibility Articulation Index vs. Channel Capacity, 65, 69
  high-frequency tone recognition, 66
  word recognition scores, 65–66, 70
Audibility without intelligibility, 71
Audiogram, 36–37, 39, 60
Audiovestibular (AV) abnormalities, 114, 118
  mitrochondrial diseases, 117, 118
  X-linked syndromes, 118
Audiovisual FM system (AudiSee), 43, 46–48
  benefits and system configuration, 48–49
  moving visual background, 49
Auditory abilities and individual differences, 84
Auditory Brainstem Responses (ABRs). *See also* Auditory Training
  Auditory nerve fiber dys-synchronization, 186–187
  auditory neuropathy, in, 184–185, 193–198, 201, 211
  obligatory evoked potentials and MLR, 267
  test modality vs. hearing test, 204–210
Auditory functions, primary elements, 84
Auditory Neuropathy (AN), 183, 198–199. *See also* Auditory Neuropathy/Auditory Dys-synchrony; Cochlea, inner hair cells, outer hair cells
  audibility vs. neuropathy, 188
  children, infants, and newborns
    age of onset and progression, 199
    clinical investigations, 196–197
    clinical protocol, multidisciplinary approach, 225–236
    jaundice and genetics, 195
    prevalence, 195–196
    risk factors and patient evaluation, 193, 195, 226
    screening and assessment programs, 197–198
  diagnostic features and associated disorders, 185
  electrophysical tests, 184–185
  etiologies, 186–187, 201
  word recognition and temporal processing, 187, 193, 201
Auditory Neuropathy/Auditory Dys-synchrony (AN/AD). *See also* Auditory Neuropathy; Masking Level Difference
  clinical investigations in children with cochlea implants, 218–222
  clinical test battery and auditory measures, 202, 205
  definition of, 201–202, 210, 215, 225–227
  diagnosis triage and differential diagnosis, 209–210
  individualized treatment management, 246–247
    auditory verbal therapy (AVT), 242–243
    cochlea implants, 209, 213, 215–223, 243–244
  mechanisms and patient identification, 206–207
  otoacoustic emissions and diagnosis, 202
    middle-ear problems, effects of, 203
  patient variation and associated disorders, 205–206, 240
  risk factors, 205
  treatment modalities, 209, 242
    cued speech and baby signs in newborns, 212, 242
Auditory plasticity, clinical investigations and cochlea implants, 264–266
Auditory Processing Disorders (APD), 277, 298, 327–328. *See also* Auditory Training; Sound-field FM amplification
  adolescents and adults
    management programs, 329–332, 359–360
    patient characteristics and co-morbid conditions, 328–329

Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Auditory Processing Disorders (APD), adolescents and adults *(continued)*
peripheral hearing loss, with, 332–334
specific subtypes and Attention Deficit Hyperactivity Disorder, 339–340
classroom acoustics evaluation and modification, 309–310
management and intervention
audiologist role, 281–282
electrophysical measures, 350–353
historical overview, 279–280
multidisciplinary approaches, 282–284, 288–294
treatment evaluations, 361–363
neurological disorder definition, 227–278
Auditory Training (AT) in auditory processing disorders, 265–266, 298–299
adolescents and adults, 330
auditory discrimination, 269
auditory evoked potentials, 267,350–352
auditory skills, neural plasticity and reorganization, 271–272
formal and informal training and techniques, 267–271, 300–306
Mismatch Negativity Potential (MMN), 267, 269, 351–352
Auditory-visual speech integration, age-related changes, 95
Aural rehabilitation, 3, 5, 10
assistive devices, 4, 9
audiology, 5
aural rehabilitation group, 5, 7, 9
hearing-aids, 4–7
advanced technology vs. conventional, 4
hearing-loss lifestyle, 4, 6

Balance system anatomy, 108
Benign Paroxysmal Positional Vertigo (BPPV), 114
biochemistry, 143, 147
calcium concentration, endolymphatic fluid and peripheral circulation, 145–147
otoconia debris, 145
otolith system and calcium carbonate crystals, 144
canalithiasis and cuplolithiasis, 103, 133
clinical research, 136–138
pathophysiology
posterior semicircular canals (PSCC), 130
treatment methods, therapeutic, 129–133, 138–139, 154
video-oculography (VNG), 133

Central Auditory Nervous System (CANS), 252, 263
cochlear nerve, parallel and hierarchical processing, 252
management of adults with APD and peripheral hearing loss, 333–334
olivary nuclei, 252–253, 255
plasticity, 253–255, 264–266
Central Auditory Processing (CAP), 251–256
Central auditory processing disorders (CAPDs), 252, 280, 319
diverse temporal processing problem, 256–257
five types of central auditory processing disorders, 320–321
management of developmental language delays, 257–259
play therapy in children, 325
management tripod, 320–324
clinical examples, 324–325
Channel capacity, 57–58, 66
cochlea implant patients, 66–67
neural function loss, 72
Signal-to-Noise Ratio, relationship to, 67–68
Chronic auditory gain, 25
Classroom Reverberation Time (RT), 44
auditory processing disorder management, 281–282
Clear vision during walking. *See* VOR
Cochlea
basilar membrane, 71, 195
dead regions, 71
endocochlear potential (EP), 194
hearing in noise, attenuation and distortion factors, 59
implant position and speech recognition, 97–98
inner hair cells (IHC), 68
auditory neuropathy, in, 186, 190, 194–195
experimental research and threshold levels, 66
missing dots (neural signals) to the brain, 68–69
outer hair cells (OCH), 68
auditory neuropathy, in, 183–187, 195
Signal-to-Noise Ratio loss, 71–72
Cochlea Microphonics (CM), 202–204, 210–211
Communication strategies in the hearing impaired, 5, 7
coping skills, 5, 8
Conversational fluency, 35, 41
auditory thresholds, 35–38, 40–41
speech intelligibility, improved, 72–74
Cortical plasticity, mechanisms and reorganization, 264–265
Critical period of developmental plasticity, 266

Deaf Pride, 9
Dizziness, patient history and diagnosis, 108–109

Erber's area, 40–41

Falls in the elderly
interventions, 170–171
risk factors and patient evaluation, 162, 164–171
statistics, morbidity and mortality, 161–162
Fast ForWord, 258–259, 268, 300

Habituation-based treatment protocol. *See* Tinnitus Retaining Therapy
Hearing aid microphone types, 78–80
Hearing aid use and benefit, 35, 37
conversational management strategies, 38–39
face-to-face conversation, 36, 39–40
unaided fluency level, 39–40
Hearing In Noise Test (HINT), 60
Hearing loss
oxidative damage, 17
experimental research, heredity and loss protection, 15
NMDA (N-methyl-D-asparate) receptor simulation and NO (nitric oxide) release, 17
prevention, 15–16
Hereditary hearing loss, 115–116
Hyperacusis, 23, 31. *See also* Tinnitus Retaining Therapy
hearing impairment, 23
Loudness Discomfort Levels, 23–24

Inter-Stimulus Intervals (ISIs), 258

Labyrinthine Storm, 150
Labyrinthitis, stabilized, 114, 151–150
Language acquisition in children, the critical period, 99
Lipreading, 95
Loudness Discomfort Level (LDL), 21, 26, 180. *See also* Hyperacusis; TRT
amplified sound tolerance, 22
gain process monitoring, 25–26
incremental shifts from Tinnitus Retaining Therapy, 23

Masking Level Difference (MLD), 202–203
Auditory Neuropathy/Auditory Dys-synchrony, 205
Meniere's Disease, chronic, 114, 150–151
Middle-and long-latency response tests, 184–185, 188–189
Middle-ear muscle reflexes (MEMR), 201–202, 207
Mini-Mental Status Examination (MMSE), 165
Missing Dots. *See* Cochlea, inner hair cells
Missing speech cues, 57–58, 66

Otoacoustic emissions (OAE) in auditory neuropathy, 183–187, 193–199. *See also* Auditory Neuropathy/Auditory Dys-synchrony; Cochlea Microphonics
loss following hearing aid use in Auditory Neuropathy, 209
oliviocochlear reflex, 205
test modality vs. hearing test, 204
transient evoked (TEOAE) and distortion product (DPOAE), 196–197, 202, 225

Perceptive Articulation Index, 58, 66
acoustical speech cue replacement, 67–68
Permanent Threshold Shift (PTS), 14
Plastic and adaptive auditory gain, 21, 24
VOR, relationship to, 25
Psychological behavior in hearing loss, 6, 9
coping difficulties, social and emotional, 6
disassociative behavior, 6
embarrassment and isolation, 6
research, 3, 9
stigmatization, 6–8, 10
PTA (Pure Tone Average), 59–60, 74
Pure-tone thresholds in Auditory Neuropathy/Auditory Dys-synchrony, 240

Quality-of-life in the hearing impaired, 5
health related measures, 8
QuickSIN (Quick Speech In Noise) Test, 60

Reaction Time (RT) measurement, P300, 164–166
Risk of Falls (ROF) assessment, 162–163, 166–169

Self-assessment questionnaire for the hearing impaired, 8
Self-efficacy in hearing loss, 6, 9
Sensory hearing loss vs. auditory neuropathy, 194–195
Signal-to-Noise Ratio (SNR)
auditory neuropathy, in, 188, 206
classroom speech-perception performance, 44
evaluation of, 60, 62–63
inner hair cell loss, 65
Pure Tone Average and Signal-to-Noise Ratio loss, ratio, 59
Sound conditioning
definition of, 13–14
experimental research, 14, 17
glutathione system, 17
hearing loss prevention, 15–16
long-term protective effects, threshold shift, 13–14
middle-ear muscle contribution, 15
olivocochlear efferent system, 15, 17
preconditioning, 13
hereditary hearing loss protection, 15
low-level sound conditioning, 17
paradigms, 14–16

Sound-field FM amplification systems, 44–45
Auditory Processing Disorder management, 281–282, 321–322, 330
classroom acoustics evaluation and modification, 313, 314
patient fitting, training and treatment evaluation, 313–316
personal FM system for Auditory Processing Disorders, indicators and patient profile, 310–313
Sound tolerance modification, dynamic range expansion, 22
Speech, frequency range of spoken English, 37
Speech In Noise (SIN), 58
Auditory Neuropathy/Auditory Dys-synchrony, 206
Auditory Processing Disorders, 281
directional microphones, 72, 77
hearing aid technology and improved speech understanding, 77–80
Signal-to-Noise Ratio relationship, 59
word recognition score, 68–69, 70, 77
Speech Intelligibility Index. *See* Articulation Index
Speech-perception performance and visual-speech cues, 45–46
Speech-recognition scores in children, 44
Speechreading (visual-alone modality), 45, 46
experimental research, 49–52
moving visual background illusion and visual backdrop, 53–54

Test of Basis Auditory Capabilities (TBAC), 85
experimental research in school-age children
academic achievement, speech-recognition, and non-speech factors, 88–90
SAT and IQ scores vs. speech perception and auditory acuity, 86–87
Threshold-Equaling Noise (TEN), 71
Tinnitus, 109
Tinnitus and hyperacusis treatment, 22–24
open-canal noise generators, 24
Tinnitus Retaining Therapy (TRT), 21, 26, 179
hearing aid use, 30–31
Loudness Discomfort Level shifts, 30
low-level broadband noise, 22
nebulous chronic adaptive auditory gain, resetting, 24
sound tolerance modification, 22

VAT-VOR system, monitoring natural head movements, 123–125
Vertigo
nonvestibular dizziness vs. vestibular dysfunction, 108–109
peripheral and central vertigo and associated symptoms, 109
Vestibular Autorotation Test (VAT), 121–123, 151
correction factors and test-retest reproducibility, 125
high-frequency VOR testing, 122–123
Vestibular disorders
common definitions, 110
hereditary problems and defects, 113, 116–118
Vestibular function
anatomical damage, 149–150
compensated vs. noncompensated, 151
control system model, 121
interacting network, physiological mechanisms, 121–122
locomotion, stabilization and proprioception, 121–122
plasticity, 122
unilateral vs. bilateral dysfunction, 149–150
Vestibular neuronitis, stabilized, 110, 114, 150–151
Vestibular Ocular Reflex (VOR), 25
Vestibular Rehabilitation Therapy (VRT)
patient rating scales, 152
physiology, central nervous system plasticity, 152–153
adaptation and substitution, 154
therapy models, clinician vs. self-directed, 155
treatment modalities, 151–152
unilateral vestibular dysfunction (UVD), 150
VOR analysis, 152
Vestibulo-Ocular Reflex (VOR), 121–122, 150. *See also* VAT; VRT
central nervous system (CNS) compensation, following vestibular dysfunction, 151
physiologically relevant high-frequency testing, 125–126
Visual ability and hearing threshold levels, 39–40